EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 206 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... October 1, 2020 What to Know About Returning to Work After Cancer Treatment: An... February 15, 2024 FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T... August 12, 2026 Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 Load more HOT NEWS “Oncometabolite” Neutralizes Immune Cells Near Tumors Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... Time to get stratified Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells
